Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONDOAC and KIDOAC study of pharmacokinetic variability during direct oral anticoagulant treatment
NL-OMON44541Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabigatran, rivaroxaban and apixaban in Atrial fibrillation (AFib), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more (3 cohorts), sponsored by Leiden University Medical Center. Primary endpoints: PT measurement, aPTT measurement and 4 more. Started Mar 2018; status: active, not recruiting.
02
Drugs
dabigatranrivaroxabanapixaban
03
Conditions
Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)Phlebothrombosis
Beyond the preview
Go deeper on NL-OMON44541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44541.